Ketamine Tablet for Chronic Pain

Ketamine tablet has a longer clinical history in pain management than in psychiatry, with use dating to the 1990s. Today it represents one of the few pharmacological options for certain types of chronic pain that are poorly responsive to conventional analgesics. Understanding its mechanisms, evidence base, and appropriate protocols helps patients and clinicians make informed decisions.

Why Ketamine Is Effective in Chronic Pain

Chronic pain, particularly neuropathic and centrally mediated pain, involves mechanisms that are poorly addressed by opioids and other analgesics. Ketamine's unique pharmacological profile targets several of these mechanisms:

NMDA Receptor Blockade

Chronic pain is associated with central sensitization — a state in which spinal cord and brain pain-processing circuits become hyperexcitable, amplifying pain signals. NMDA receptors are critical mediators of central sensitization. By blocking NMDA receptors in spinal dorsal horn neurons and supraspinal pain circuits, ketamine directly addresses the underlying mechanism of central sensitization.

This is why ketamine can provide analgesia even when opioids have failed or provided inadequate relief — it is working at a different mechanistic level.

Opioid System Interactions

Ketamine interacts with opioid receptors at therapeutic concentrations:

• Weak agonism at μ-opioid receptors contributes to analgesia
• Antagonism at κ-opioid receptors may modulate pain processing and dysphoria
• Importantly, ketamine reduces opioid tolerance by blocking the NMDA receptor-mediated process through which opioid receptors become desensitized

This makes ketamine tablet a valuable adjunct for patients on chronic opioid therapy who are developing tolerance. For a deeper exploration of this relationship, see our article on ketamine tablet and opioid dependence.

Anti-Inflammatory Effects

Ketamine has documented anti-inflammatory properties, including reduction of microglial activation in the central nervous system. Neuroinflammation contributes to the maintenance of chronic pain states, and ketamine's anti-inflammatory effects may contribute to longer-term pain relief.

Conditions Where Ketamine Tablet Is Used

Complex Regional Pain Syndrome (CRPS)

CRPS — particularly Type I (reflex sympathetic dystrophy) and Type II — is characterized by disproportionate, often debilitating pain typically following injury or surgery. Central sensitization is a core mechanism, making CRPS one of the strongest indications for ketamine therapy.

Evidence for ketamine tablet in CRPS includes multiple case series and small open-label trials demonstrating meaningful pain reduction. Some patients with refractory CRPS achieve durable relief with a combination of IV induction followed by oral maintenance.

Typical oral CRPS protocol:

• Dose: 20–100 mg 2–3 times daily
• Duration: Ongoing; assessed every 1–3 months
• Adjunctive: Physical therapy remains essential for CRPS

Neuropathic Pain Syndromes

Diabetic peripheral neuropathy: Small trials and case series support ketamine tablet for painful diabetic neuropathy, showing reduction in NRS pain scores and sometimes improvement in nerve conduction parameters.

Postherpetic neuralgia: The central sensitization component of postherpetic neuralgia is amenable to NMDA blockade. Ketamine tablet at 30–100 mg 2–3 times daily has shown benefit in case series.

Chemotherapy-induced peripheral neuropathy (CIPN): Emerging evidence suggests ketamine may prevent and treat the central sensitization component of CIPN.

Central post-stroke pain: Case reports support ketamine tablet for this notoriously difficult pain syndrome.

Phantom limb pain: Both the central sensitization and possible opioid receptor contributions make phantom limb pain a potential ketamine tablet indication.

Fibromyalgia

Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive symptoms — all underpinned by central sensitization. Ketamine tablet at low doses has shown analgesic and symptom-relieving effects in small studies, though fibromyalgia evidence is less robust than for CRPS or neuropathic pain.

Opioid-Refractory Cancer Pain

Palliative care has the longest history with ketamine tablet in pain. For cancer patients with pain unresponsive to opioids — often neuropathic in character — ketamine tablet provides an additional analgesic option that can be administered at home.

Typical palliative pain protocol:

• Starting dose: 10–30 mg 3–4 times daily
• Titration: Increase by 10–30 mg/dose every few days to effect
• Maximum in palliative context: 200–600 mg/day (higher than psychiatric protocols)
• Combined with adjuvants (gabapentin, tricyclic antidepressants, topical agents) as appropriate

Dosing for Chronic Pain: The "Sub-Anesthetic" Range

Pain management ketamine tablet protocols use doses specifically designed to avoid significant psychoactive effects while maintaining analgesic benefit — the "sub-anesthetic" or "analgesic" dose range.

Ultra-Low Dose (Anti-Hyperalgesic)

• Range: 5–30 mg per dose
• Frequency: 3–4 times daily
• Goal: Block NMDA-mediated central sensitization without dissociation
• Applications: Fibromyalgia, opioid tolerance reduction, mild neuropathic pain

Low to Moderate Dose (Analgesic)

• Range: 30–100 mg per dose
• Frequency: 2–3 times daily
• Goal: Direct analgesic effect plus central sensitization reversal
• Applications: CRPS, postherpetic neuralgia, cancer pain

Higher Dose (Refractory Pain)

• Range: 100–200 mg per dose
• Frequency: 2–3 times daily
• Applications: Refractory CRPS, palliative care, severe neuropathic pain
• Requires monitoring for psychoactive effects and bladder toxicity

Monitoring During Pain Treatment

Chronic pain patients on ketamine tablet require monitoring distinct from psychiatric patients:

Pain Assessment

• NRS (0–10 numeric rating scale) pain diary
• Brief Pain Inventory at monthly intervals
• Functional assessment: mobility, activities of daily living, sleep quality

Urological Monitoring

Bladder toxicity (ketamine cystitis) is a particular concern in chronic pain patients who often use higher doses:

• Baseline urinalysis and bladder symptom questionnaire before starting
• Urological review if symptoms develop
• Periodic urinalysis every 3–6 months for patients on higher doses
• Cystoscopy if significant symptoms develop

Cognitive Function

Some chronic pain patients, particularly older adults, are sensitive to the cognitive effects of ketamine. Brief cognitive screening at baseline and periodically during treatment is prudent.

Liver Function

Chronic use may affect hepatic enzyme levels. LFT monitoring every 6 months is reasonable for long-term treatment.

Combining Ketamine Tablet with Other Pain Medications

Ketamine tablet is most effective as part of a multimodal pain management approach:

Safe combinations:

• Gabapentinoids (gabapentin, pregabalin): Complementary mechanisms; monitor for additive CNS depression
• NSAIDs: No significant interaction; may have additive anti-inflammatory benefit
• Tricyclic antidepressants: Monitor for additive CNS effects; beneficial combination for neuropathic pain
• SNRI antidepressants: No significant interaction; often coprescribed

Caution required:

• Benzodiazepines: Additive CNS depression; use lowest effective doses
• Opioids: Concurrent use is common and often appropriate (ketamine reduces opioid tolerance); monitor for excessive sedation
• Tramadol: Lowers seizure threshold; caution with concurrent use

When to Expect Response

For chronic pain, ketamine tablet typically produces:

• Initial pain reduction within the first 1–2 weeks
• Plateau of response at 4–8 weeks
• Need for ongoing maintenance dosing to sustain benefit (effects typically do not persist long after discontinuation)
• Some patients achieve prolonged remission of CRPS symptoms after a sustained course

Setting realistic expectations — significant improvement in many patients but rarely complete elimination of chronic pain — is part of appropriate pre-treatment counseling.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches